Technology

Samsung Bioepis gets nod for sale of ophthalmology biosimilar drug in Europe

Samsung Bioepis gets nod for sale of ophthalmology biosimilar drug in Europe

South Korean biopharmaceutical firm Samsung Bioepis Co. said Monday it has won approval from European authorities for the sale of its ophthalmology biosimilar, Byooviz. The European Commission granted the marketing authorization on ranibizumab biosimilar, previously known as SB11, which references Swiss pharmaceutical giant Novartis' blockbuster medication Lucentis.

Click here to read more -->
×